Centre for Synthetic Biology and Innovation, South Kensington, Imperial College London, UK.
Integr Biol (Camb). 2011 Feb;3(2):109-18. doi: 10.1039/c0ib00070a. Epub 2011 Jan 19.
The assembly of DNA from small fragments into large constructs has seen significant recent development, becoming a pivotal technology in the ability to implement the vision of synthetic biology. As the cost of whole gene synthesis is decreasing, whole genome synthesis at the other end of the spectrum has expanded our horizons to the prospect of fully engineered synthetic cells. However, the recently proven ability to synthesise genome-scale DNA is at odds with our ability to rationally engineer biological devices, which lags significantly behind. Most work in synthetic biology takes place on an intermediate scale with the combinatorial construction of networks and metabolic pathways from registries of modular biopart components. Implementation for rapid prototyping of engineered biological circuits requires quick and reliable DNA assembly according to specific architectures. It is apparent that DNA assembly is now a limiting technology in advancing synthetic biology. Current techniques employ standardised restriction enzyme assembly protocols such as BioBricks™, BglBricks and Golden Gate methods. Alternatively, sequence-independent overlap techniques, such as In-Fusion™, SLIC and Gibson isothermal assembly are becoming popular for larger assemblies, and in vivo DNA assembly in yeast and bacillus appears adept for chromosome fabrication. It is important to consider how the use of different technologies may impact the outcome of a construction, since the assembly technique can direct the architecture and diversity of systems that can be made. This review provides a critical examination of recent DNA assembly strategies and considers how this important facilitating aspect of synthetic biology may proceed in the future.
从小片段将 DNA 组装成大片段的技术最近取得了重大进展,成为实现合成生物学愿景的关键技术。随着全基因合成成本的降低,另一端的全基因组合成将我们的视野扩展到了完全工程化的合成细胞的前景。然而,最近证明的合成基因组规模 DNA 的能力与我们合理设计生物器件的能力不一致,后者明显滞后。合成生物学中的大多数工作都处于中间规模,通过组合来自模块化生物部件库的网络和代谢途径进行。根据特定的架构进行工程生物电路的快速原型制作需要根据特定的架构快速可靠地进行 DNA 组装。显然,DNA 组装现在已经成为推进合成生物学的限制技术。目前的技术采用标准化的限制酶组装协议,如 BioBricks™、BglBricks 和 Golden Gate 方法。或者,序列无关的重叠技术,如 In-Fusion™、SLIC 和 Gibson 等温组装,对于较大的组装越来越受欢迎,而酵母和芽孢杆菌中的体内 DNA 组装似乎擅长染色体制造。重要的是要考虑不同技术的使用如何影响构建的结果,因为组装技术可以指导可以构建的系统的架构和多样性。这篇综述批判性地考察了最近的 DNA 组装策略,并考虑了合成生物学中这一重要的促进方面未来可能如何发展。